CD8A and neoplasm: Mounting evidence indicates that tumors co-opt multifaceted pathways, including metabolic reprogramming, cytokine induction, receptor modulation, and immune checkpoint activation, to systemically impair CD8+ T cell effector function, thereby fostering tumor progression.